Illuminating pathways to reproductive health

Infertility affects approximately 10%-15% of couples throughout the United States, and 30%-40% of infertility is caused by a combination of male and female factors.1 We can help you provide the insights your patients may need as they are starting their families.

male and female fertility

ReproSource®: Center of Excellence

Quest Diagnostics Center of Excellence for fertility testing, ReproSource®, offers you access to a network of experts who can help you:

  • Identify patients at risk of having a diminished egg supply or semen count
  • Better manage patient expectations when discussing voluntary delays in childbirth
  • Better identify genetic, immune, and hematologic causes of recurring pregnancy loss
  • Access convenient semen testing for your patient’s reproductive partner

Leading edge research and guidelines ensure you have access to high quality:

Female fertility testing

Female fertility testing requires the careful evaluation of multiple organ systems, as well as a combination of diagnostic techniques. This includes the careful evaluation of reproductive anatomy and patient history by a trained fertility specialist, as well as accurate blood testing from a clinical laboratory exclusively focused on fertility testing.

A critical component of female fertility testing includes the accurate evaluation of ovarian reserve and ovulatory egg supply. ReproSource has invested heavily in conducting extensive egg supply research, and in developing calibrated and validated testing for the accurate evaluation of ovulatory egg supply.

Click the name of the egg supply test to learn more.

Ovarian Assessment Report (OAR)

The Ovarian Assessment Report (OAR) provides a highly accurate assessment of a woman’s ovulatory egg supply using a single blood sample. The OAR provides results from both routine diagnostics, such as FSH, and advanced hormone tests such as AMH. The OAR also includes age to provide an Egg Supply Score (ESS) which allows for a more accurate estimate of a woman’s available egg supply.

The OAR helps you accurately assess egg supply status for patients:

  • Currently struggling with fertility
  • Proactively planning for future pregnancy
  • Monitoring their reproductive health

Ovarian Assessment Report

Visit ReproSource.com for detailed information about the OAR that is best for you and your patients.

Anti-Müllerian Hormone (AMH) testing

ReproSource is a pioneer in establishing the clinical utility of AMH for fertility specialists and has calibrated the assay results to the number of eggs retrieved through ovarian hyperstimulation.

Although AMH has quickly been established as the most reliable single hormone measure of ovarian reserve, ReproSource continues to conduct research to develop more meaningful cutoff ranges for clinical conditions such as ovarian hyperstimulation syndrome (OHSS) and polycystic ovarian syndrome.

Why use ReproSource for AMH testing?

  • Experience in validating and calibrating multiple kits
  • Meaningful reporting ranges and comments
  • Continual research to benefit fertility specialists
  • Rapid turnaround
  • Superior laboratory technical performance
  • Outstanding client service support

Visit ReproSource.com for more information on AMH research and ovarian reserve testing.

ReproSource is a national leader in specialty fertility diagnostic services. While ReproSource is a Quest Diagnostics affiliate, ReproSource and Quest are separate companies. As such, health plan access, test ordering, and billing processes may differ from those of Quest Diagnostics. Please note that ReproSource is not a Medicare/Medicaid provider. For more information, please contact ReproSource at 1.800.667.8893 or visit ReproSource.com/Contact.

Learn more about ReproSource female fertility testing

Male fertility testing

Male fertility testing includes innovative semen and genetic testing coupled with robust and informative reporting that allows clinicians to quickly interpret test results and effectively communicate those results using patient-friendly language and graphics. Additionally, the andrology research and product development teams at ReproSource have developed male fertility testing solutions that feature:

Click the test name to learn more.

Advanced Semen Report

The Advanced Semen Report 2.0 is a unique ReproSource panel that provides an evaluation of multiple semen parameters that have been shown to affect a couple’s likelihood of success with natural conception and intrauterine insemination (IUI).

Our proprietary Advanced Semen Report measures DNA fragmentation and ROS damage using only a single specimen, offering clinicians and patients more accurate expectations of IUI success. Clinical research indicates that abnormal DNA fragmentation index (DFI) scores predict a poor chance of success with IUI but improved intracytoplasmic sperm injection success relative to conventional IVF.

Visit ReproSource.com for more information on the Advanced Semen Report.

Advanced Semen ReportAdvanced Semen Report

Semen analysis with @Home Collection

The semen analysis with @Home Collection is ideal for remote patients that are unable or prefer not to provide a semen specimen at a fertility treatment center or local laboratory. The semen analysis with @Home Collection utilizes a proprietary media and process that preserves semen parameters to ensure an accurate semen analysis the day after specimen collection, providing a highly accurate and convenient semen analysis alternative.

A comprehensive semen analysis:

  • Concentration
  • Motility
  • Morphology (Kruger Strict)
  • Inflammation markers
  • Viability

The @Home Collection option is ideal for:

  • Remote patients that cannot/prefer not to drive into the office
  • Clinics without on-site semen analysis capabilities
  • Pre- and post-vasectomy patients
  • Patients who simply prefer the privacy of collecting at home

Easy and affordable:

  • No need to stock supplies in your office
  • Fax in a completed requisition form to order
  • Results ready in 1 to 2 business days
  • Fax, EMR, and web reporting
  • Most insurances accepted

Click here to learn more information about the robust validation studies or to order tests and panels.

Genetics

ReproSource also offers unique male fertility testing that accurately identifies the genetic factors that impact male fertility. The ReproSource Y-Chromosome MicroDeletions (YCMD3.0) test was developed in collaboration with world renowned scientists in the field of Y chromosome research.

In both azoospermic and oligospermic patients, the ReproSource Y-Chromosome MicroDeletions (YCMD3.0) test:

  • Reduces high false positive rates
  • Identifies more deletions of clinical importance
  • Provides guidance on TESE consideration

ReproSource also provides chromosome karyotyping services. A karyotype is also recommended along with a Y microdeletion study for azoospermic or severely oligospermic males.

Visit ReproSource.com today to learn more about high quality, innovative diagnostic testing coupled with unparalleled service and commitment to excellence.

ReproSource is a national leader in specialty fertility diagnostic services. While ReproSource is a Quest Diagnostics affiliate, ReproSource and Quest are separate companies. As such, health plan access, test ordering, and billing processes may differ from those of Quest Diagnostics. Please note that ReproSource is not a Medicare/Medicaid provider. For more information, please contact ReproSource at 1.800.667.8893 or visit ReproSource.com/Contact.

Learn more about ReproSource male fertility testing

​References:

  1. What you need to know about infertility. American Pregnancy Association. Published July 24, 2019. Accessed October 15, 2020. https://americanpregnancy.org/infertility/what-you-need-to-know-about-infertility-68352/